Low-Dose Ribavirin Treatments Attenuate Neuroinflammatory Activation of BV-2 Cells by Interfering with Inducible Nitric Oxide Synthase

Table 1

Release of TNF-α from activated BV-2 cells treated with RBV.

Groups	C	LPS	LPS + 0.1 μM RBV	LPS + 1 μM RBV	LPS + 10 μM RBV
TNF-α (pg/mL)	50 ± 23	2110 ± 95	2114 ± 59	2361 ± 84	2157 ± 175

versus control group (C).